Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Cadrenal Therapeutics (Nasdaq: CVKD) will participate in the virtual Lytham Partners Spring 2026 Investor Conference on May 28, 2026.

Rhea-AI Summary

Cadrenal Therapeutics (Nasdaq: CVKD) will participate in the virtual Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The company will deliver a webcast presentation and hold one-on-one investor meetings.

The webcast is scheduled for 9:30 a.m. ET and will be available for replay.

Argus May 20 session

+3.82% close to close Open Argus

Details

News Market Reaction – CVKD

In the May 20 session, CVKD gained 3.82%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Cadrenal’s participation at the Lytham Partners Spring 2026 Investor Co...

Analysis

This announcement highlights Cadrenal’s participation at the Lytham Partners Spring 2026 Investor Conference on May 28, 2026, providing a platform to discuss CAD-1005’s planned Phase 3 program and recent financing steps. Recent filings noted operating losses, limited cash of $2.3 million, and warrant-related transactions tied to an effective Form S-3 registering 1,180,003 resale shares. Investors may monitor future clinical milestones, additional funding actions, and any updates on regulatory timelines.

Key Figures

Conference date: May 28, 2026 Webcast time: 9:30 a.m. ET Current price: $4.97 +5 more

Conference date

May 28, 2026

Lytham Partners Spring 2026 Investor Conference webcast date

Webcast time

9:30 a.m. ET

Scheduled start time for company webcast presentation

Current price

$4.97

Price before conference participation announcement

52-week range

$4.21 – $16.25

52-week low and high prior to this news

Registered resale shares

1,180,003 shares

Shares of common stock registered on Form S-3 for resale

Investor warrant shares

1,142,860 shares

Shares issuable upon exercise of Investor Warrants under S-3

Placement agent shares

37,143 shares

Shares issuable upon exercise of Placement Agent Warrants

Shares outstanding

3,078,247 → 4,258,250

Outstanding shares as of Apr 1, 2026 and post-full warrant exercise

Historical Context

5 past events · Latest: May 07

5 events

1. May 07

   Q1 results & Phase 3 plan

   24h Move

   -2.4%

   Q1 2026 results and detailed Phase 3 CAD-1005 development update.

2. Apr 30

   End-of-Phase 2 outcome

   24h Move

   +19.3%

   Completed End-of-Phase 2 FDA meeting and Phase 3 registration path.

3. Mar 31

   FY results & CAD-1005

   24h Move

   +20.5%

   Q4 and full-year results plus CAD-1005 program and FDA feedback.

4. Mar 12

   12-LOX obesity research

   24h Move

   -8.0%

   Preclinical 12-LOX data in obesity and Type 2 diabetes inflammation.

5. Mar 02

   Platform expansion update

   24h Move

   +1.2%

   Expansion of 12-LOX inhibitor platform and blinded Phase 2 CAD-1005 data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.

Company Webcast

The webcast presentation will take place at 9:30 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2026/ or directly at https://app.webinar.net/DxpqArQk70e. The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/spring2026invreg/.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also in development for chronic indications.

The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and left ventricular assist devices, and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings.

For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

For more information, please contact:

Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Cadrenal Therapeutics (CVKD) present at the Lytham Partners Spring 2026 Investor Conference?

Cadrenal Therapeutics will present via webcast on May 28, 2026, at 9:30 a.m. ET. According to Cadrenal Therapeutics, the event is part of the Lytham Partners Spring 2026 virtual investor conference and will include a replay option.

How can investors access the Cadrenal Therapeutics (CVKD) webcast on May 28, 2026?

Investors can access the Cadrenal Therapeutics webcast through the Lytham Partners Spring 2026 conference homepage or directly via the provided webinar link. According to Cadrenal Therapeutics, the webcast will also be available for replay after the live event.

Will the Cadrenal Therapeutics (CVKD) investor presentation be available for replay?

Yes, the Cadrenal Therapeutics investor webcast will be available for replay following the May 28, 2026 presentation. According to Cadrenal Therapeutics, investors can use the same conference or direct webinar links to view the recorded session afterward.

How can investors schedule one-on-one meetings with Cadrenal Therapeutics (CVKD) at the Lytham conference?

Investors can request one-on-one meetings with Cadrenal Therapeutics management by contacting Lytham Partners at the 1x1@lythampartners.com email address. According to Cadrenal Therapeutics, investors may also register for the event via the Lytham Partners Spring 2026 registration link.

What type of event is the Lytham Partners Spring 2026 Investor Conference for Cadrenal Therapeutics (CVKD)?

The Lytham Partners Spring 2026 Investor Conference is a virtual investor event featuring a webcast and one-on-one meetings. According to Cadrenal Therapeutics, the company will present its business and meet individually with investors throughout the May 28, 2026 conference.